Yes, that's right. I had thought that one of the recent raises or extensions had included warrants expiring in one year from the date of the raise/extension.

I didn't find anything regarding the second portion of the previous post: an expiration to the BTD or required timeframe for the beginning of the directed trial.

One would think that if the FDA has a very high opinion about 208, and is genuinely concerned with using BTD to get 208 into use in order to help many, many potential beneficiaries, that they would want this thing moving.

Of course I'm interested as a profit motivation, but looking at the MACE reduction numbers and the striking synergy with SGLT2...it is a travesty for patients to be without it. 

Here we sit a year later. What a shame.